PEG-MGF

Mechano Growth Factor, Pegylated (PEG-MGF): an unapproved, investigational and chemically underdefined polyethylene-glycol-conjugated derivative of an IGF-1Ec E-domain peptide. The canonical native 24-amino-acid MGF sequence is YQPPSTNKNTKSQRRKGSTFEERK, but published PEGylated research constructs and products sold as PEG-MGF may use different sequences, stereochemistry, terminal modifications, PEG sizes, and conjugation chemistries and are not interchangeable with mature IGF-1, full-length IGF-1Ec, native MGF E-peptide, or MGF amide.

Overview

The central scientific and compliance problem with PEG-MGF is that the name collapses several materially different interventions into one market concept. Human exercise studies measured IGF-1 splice-variant messenger RNA in muscle biopsies. Early cell papers tested short E-domain peptides. Other studies used full-length, non-natural MGF proteins, gene expression, local polymer delivery, or unmodified E-peptides. The closest published PEGylated intervention used a 24-amino-acid mammalian-consensus peptide with D-arginine substitutions, N-terminal PEGylation, and C-terminal amidation in gerbil brain ischemia. None of those findings automatically establishes the identity, pharmacology, dose, safety, or efficacy of a current PEG-MGF vial used for muscle recovery. [Hameed et al., 2003; Dłużniewska et al., 2005; Janssen et al., 2016; Doroudian et al., 2014]

The current U.S. regulatory posture is cautionary. FDA lists Mechano Growth Factor Pegylated under bulk drug substances nominated but withdrawn from the agency's Category 2 process and states that compounded PEG-MGF may pose significant immunogenicity risk, presents peptide-impurity and active-pharmaceutical-ingredient characterization complexity, and has no human exposure data identified by FDA for any route. The agency has separately placed native Mechano growth factor, not PEG-MGF, in Category 3 as a substance nominated without adequate support. Neither status is approval, Category 1 placement, or a validated pathway for patient-facing treatment claims. [FDA, 2026]

PEGylation does not solve the evidence problem by itself. Covalent attachment of polyethylene glycol can increase hydrodynamic size and alter clearance, distribution, solubility, steric access, and apparent exposure, but those effects depend on PEG molecular mass, branching, site of attachment, conjugation chemistry, and the peptide being modified. PEG can also introduce its own immune-recognition questions, including anti-PEG antibodies, accelerated clearance, and hypersensitivity-related risk. No validated human PEG-MGF pharmacokinetic profile, terminal half-life, bioavailability, or route-specific exposure target was identified. Market claims that the compound has a specific 24-, 48-, or 72-hour half-life should therefore be treated as protocol culture, not established clinical pharmacology. [Gao et al., 2024; Gaballa et al., 2024; FDA, 2014; Paragon Sports Medicine, 2026]

The strongest human anchor is still endogenous biology: resistance exercise and muscle injury can change local IGF-1 splice-variant expression. That supports the statement that the IGF-1 gene participates in mechanically responsive muscle biology. It does not show that injected PEG-MGF activates satellite cells, builds muscle, improves recovery, treats sarcopenia, or selectively targets the muscle group trained that day. The direct cell evidence is also conflicted: early studies reported proliferative effects of E-peptide constructs, while an independent pharmaceutical-industry replication found no effect of native or stabilized MGF peptides on myoblast or primary muscle-stem-cell proliferation, differentiation, or ERK activation. [Hameed et al., 2003; Yang and Goldspink, 2002; Kandalla et al., 2011; Fornaro et al., 2014]

PEG-MGF remains an unapproved, investigational, product-definition problem with no identified same-molecule human therapeutic dataset. FDA plans a Pharmacy Compounding Advisory Committee meeting before the end of February 2027 to discuss PEG-MGF and four other substances for possible inclusion on the 503A bulks list, but committee recommendations are non-binding and do not create drug approval. Athlete-facing content should note that the 2026 World Anti-Doping Agency Prohibited List names mechano growth factors under the growth-factor category prohibited at all times. [FDA, 2026; WADA, 2026]

What it is

Mechano growth factor is a name applied to biology arising from alternative processing of the IGF1 gene. In humans, the term is usually linked to the IGF-1Ec splice variant and its unique C-terminal E-domain. NCATS Inxight Drugs lists a validated 24-amino-acid "Mechano Growth Factor" peptide record with the sequence YQPPSTNKNTKSQRRKGSTFEERK and aliases including IGF-1-EC, IGF-1EC, and MGF. [NCATS Inxight Drugs, 2025]

The name does not settle whether an endogenous free 24-amino-acid E-peptide is generated, at what concentration, in which tissue, or with what receptor. The literature has used "MGF" to refer variously to the transcript, a pro-IGF-1Ec product, the isolated 24-amino-acid C-terminal segment, full-length recombinant constructs, and synthetic analogues. [Matheny et al., 2010]

PEG-MGF adds another identity layer. PEGylation means covalent attachment of polyethylene glycol, but that description is incomplete without the PEG molecular mass, branching or polydispersity, attachment site, linker chemistry, degree of substitution, peptide sequence, stereochemistry, terminal state, counterions, residual conjugation reagents, and the proportions of free peptide and free PEG. A generic name therefore cannot support one formula, one molecular weight, one half-life, or one potency statement. [Gao et al., 2024; FDA, 2014]

The most PEG-MGF-like peer-reviewed construct was not the NCATS canonical native sequence. Dłużniewska and colleagues used the mammalian-consensus sequence with substituted D-arginine residues, amidated the C-terminus, and PEGylated the N-terminus in a chemically stabilized neuroprotection construct. That construct should be named exactly as such — it is not proof for uncharacterized PEG-MGF sold for subcutaneous muscle-recovery use. [Dłużniewska et al., 2005]

How it's proposed to work

The best-supported mechanistic backbone begins upstream of any injectable product: mechanical loading and muscle damage can alter local IGF1 transcription and splice-variant expression. Human resistance-exercise biopsy work reported an acute increase in MGF-associated messenger RNA, with age-related differences, while rodent overload and injury work linked IGF-1 splice-variant expression to satellite-cell activation. These findings support a mechanically responsive IGF1 gene program. They do not demonstrate that the free E-peptide mediates the entire response or that exogenous PEG-MGF reproduces it. [Hameed et al., 2003; Hill and Goldspink, 2003]

The isolated E-peptide mechanism is less settled. Yang and Goldspink reported that an MGF E-peptide promoted myoblast proliferation while mature IGF-1 favored differentiation. Kandalla and colleagues later reported activation and greater fusion potential in cultured human muscle progenitor cells. But Fornaro and colleagues tested native and stabilized peptides across multiple cell systems and found no apparent proliferative, differentiation-delaying, or ERK-activating effect. Both findings deserve to be carried together rather than treating the early positive result as established satellite-cell pharmacology. [Yang and Goldspink, 2002; Kandalla et al., 2011; Fornaro et al., 2014]

Receptor language is also molecule-specific. Full-length MGF constructs can activate the IGF-1 receptor and, at high concentrations, insulin receptors, because they retain mature IGF-1 sequence. In Janssen and colleagues' comparison, short human and Goldspink-derived MGF peptides did not activate IGF-1 or insulin receptors under the tested conditions. That finding undercuts the common market shortcut that PEG-MGF is simultaneously "IGF-1-like" and free of IGF-1-pathway uncertainty. [Janssen et al., 2016]

The PEGylated brain-ischemia paper suggests a different mechanistic possibility, but only for its exact construct. In gerbils, the chemically stabilized N-terminally PEGylated, D-arginine-substituted, amidated consensus peptide was administered into the carotid artery immediately after reperfusion and was associated with greater hippocampal-neuron survival. The paper supports an IGF-1-receptor-independent preclinical neuroprotection hypothesis for that analogue; it does not validate generic PEG-MGF as a muscle drug, and the authors explicitly stated that the timing and administration route were not clinically applicable. [Dłużniewska et al., 2005]

Common forms in circulation

FDA currently names "Mechano Growth Factor Pegylated (PEG-MGF)" as a withdrawn nomination on its compounding-risk page and as one of five substances planned for a future PCAC discussion. FDA separately lists "Mechano growth factor (MGF)" in Category 3, the section for substances nominated without adequate support. [FDA, 2026]

Current clinic and market pages describe PEG-MGF as a lyophilized vial, usually paired with subcutaneous use, post-training timing, local targeting, or generalized recovery protocols. These descriptions document how PEG-MGF is being commercialized; they do not establish product equivalence, sterile quality, validated dosing, human pharmacokinetics, or efficacy. [Evolve Health and Wellness Clinic, 2026; Focal Point Vitality, 2026; Paragon Sports Medicine, 2026; Alpha Carbon Labs, 2026]

Names and aliases

Names and variants include PEG-MGF, PEG MGF, Pegylated Mechano Growth Factor, PEGylated IGF-1Ec E-peptide, MGF, MGF-E, IGF-1Ec, IGF-1-EC, mechano-growth factor E-domain peptide, MGF amide, full-length MGF, and stabilized MGF. These labels are not automatically chemically equivalent. "PEGylated" is especially incomplete without the conjugation specification. [NCATS Inxight Drugs, 2025; Dłużniewska et al., 2005; Thevis et al., 2014]

Common pairings in protocol and bodybuilding discourse include IGF-1 LR3, GH secretagogues such as CJC-1295 or ipamorelin, growth-hormone-releasing peptides, BPC-157, TB-500, anabolic-androgenic agents, and nutrition or training "stacks." Those pairings are evidence of category behavior, not controlled combination regimens. [Path to Peptides, 2026; The Guardian, 2026]

Regulatory status

As of July 13, 2026, no FDA-approved human PEG-MGF indication or labeled drug product was identified. FDA's own materials place PEG-MGF in a compounding-risk and future advisory-review context. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing in the way it does for approved products. [FDA, 2026]

FDA's "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" page lists PEG-MGF under bulk drug substances nominated but withdrawn. FDA states that compounded PEG-MGF may pose significant immunogenicity risk for certain routes, may be complex with respect to peptide-related impurities and API characterization, and has no human exposure data identified by FDA for any route. [FDA, 2026]

The 503A bulks document adds a separate distinction: "Mechano growth factor (MGF)" is in Category 3, meaning the substance was nominated without adequate support. PEG-MGF is not listed in current Category 1. A withdrawn nomination does not erase the safety-information gap, and Category 3 is not a permissive or evidence-positive category. [FDA, 2026]

Athlete-facing content requires a separate regulatory-governance note. The 2026 WADA Prohibited List names mechano growth factors under S2, peptide hormones, growth factors, related substances, and mimetics. The prohibition applies at all times, in and out of competition. [WADA, 2026]

FDA states that it will host a Pharmacy Compounding Advisory Committee meeting before the end of February 2027 to discuss cathelicidin LL-37, GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF for possible inclusion on the 503A bulks list. The meeting is not a drug-approval review. FDA describes advisory committees as sources of independent expert advice whose recommendations are non-binding. [FDA, 2026]

Safety

Human therapeutic safety has not been established for PEG-MGF. FDA's primary concerns are immunogenicity, peptide-related impurities, API characterization, and the absence of identified human exposure data. Product-quality risks add sterility, endotoxin, contamination, potency, and misidentification concerns. PEGylation adds the possibility of anti-PEG antibodies, altered clearance, complement activation, and hypersensitivity. [FDA, 2026; FDA, 2014; Gaballa et al., 2024]

The growth-factor context requires careful but non-speculative safety framing. Full-length MGF can activate IGF-1 and insulin receptors at high concentrations, while short E-peptides may not; generic PEG-MGF may not be one of either. That uncertainty means it is not defensible to promise "no IGF-1 side effects," "no glucose effect," or "no tumor risk." [Janssen et al., 2016; FDA, 2026]

Purported benefits, by evidence

Key literature

Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SDR. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol. 2003;547(Pt 1):247-254. Resistance exercise altered IGF-1 splice-variant messenger RNA in human muscle; age-related comparison.

Dłużniewska J, Sarnowska A, Beresewicz M, et al. A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. FASEB J. 2005;19(13):1896-1898. Neuroprotection with a D-arginine-substituted, amidated, N-terminally PEGylated consensus peptide given intra-carotid after reperfusion.

Carpenter V, Matthews K, Devlin G, et al. Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart Lung Circ. 2008;17(1):33-39. Preclinical cardiac function signal from MGF-related intervention in acute MI in a sheep model.

Matheny RW Jr, Nindl BC, Adamo ML. Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology. 2010;151(3):865-875. Nomenclature, processing uncertainty, proposed functions, and evidence-transfer cautions.

Deng M, Zhang B, Wang K, et al. Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits. Int Orthop. 2011;35(7):1099-1106. Preclinical osteoblast and bone-healing signal for an E-peptide.

Fornaro M, Hinken AC, Needle S, et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab. 2014;306(2):E150-E156. No apparent effect of native or stabilized peptides on multiple myoblast and primary stem-cell assays.

Janssen JAMJL, Hofland LJ, Strasburger CJ, van den Dungen ESR, Thevis M. Potency of full-length mechano growth factor to induce maximal activation of the IGF-I receptor is similar to recombinant human IGF-I at high equimolar concentrations. PLoS One. 2016;11(3):e0150453. Full-length MGF can activate IGF-1R and insulin receptors at high concentration; short MGF peptides did not in the tested systems.

References

• U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current April 22, 2026.
• U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026.
• U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee. Content current April 15, 2026.
• NCATS Inxight Drugs. MECHANO GROWTH FACTOR, UNII Q86M4KXC2P; MECHANO GROWTH FACTOR AMIDE, UNII Y65LH7J9BL. Records created and edited April 2, 2025.
• World Anti-Doping Agency. The 2026 Prohibited List: International Standard. Effective January 1, 2026.
• Gao Y, Joshi M, Zhao Z, Mitragotri S. PEGylated therapeutics in the clinic. Bioeng Transl Med. 2024;9(1):e10600.
• The Guardian. "People are turning themselves into lab rats": the injectable peptides craze sweeping the US. February 5, 2026; and What are peptides, are they safe and is there evidence to back up the hype? April 4, 2026.